SEP 20, 2020 8:30 AM PDT

New Drug Combo Prolongs Survival with Advanced Kidney Cancer

WRITTEN BY: Annie Lennon

Biopharmaceutical company Bristol-Myers Squibb has found that a new drug combination can reduce death rates among those with advanced kidney cancer. 

During trials, immunotherapy drug Opdivo and kinase inhibitor Cabometyx were shown to reduce the risk of death by kidney cancer by 40% when compared to Sutent, also a kinase inhibitor, and the former standard of care by Pfizer. Patients on the combination lived twice as long without their cancer progressing- an average of 16.6 months as opposed to 8.3 months for those on Sutent. 

More than this, twice as many patients on Opdivo-Cabometyx responded to the treatment and saw long-lasting effects. While 27% of trial patients responded to Sutent, 56% benefited from the new drug combination. All in all, those on the combo responded for a median of 20.2 months, whereas those on Sutent responded for a median of 11.5 months. 

As such, Bristol Myers is currently in the process of gaining the treatment FDA approval for the treatment and is advocating its use among those with advanced kidney cancer.  

Although promising, the new drug combination seems to have similar efficacy to Merck’s own drug combination- Keytruda, an immunotherapy drug, and Inlya, a kinase inhibitor by Pfizer. Together, these drugs were able to cut the risk of death by between 41% and 46% among patients with the condition. 

“The various combination treatments will unlikely be compared head-to-head,” says Toni Choueiri, MD of Dana-Farbar Cancer Institute and author of the Opdivo-Cabometyx trial. “But I think the quality of life could differentiate this new therapy, as there was a statistical significance favoring the combination arm with both questionnaires we used.”

Despite the optimism, many in the medical community are still uncertain as to whether treating cancer with two immunotherapies or immunotherapy alongside a kinase-inhibiting drug is better. However, as both seem to have similar effectiveness, some say that both should nevertheless be seen as a standard of care for first-line patients. 

 

Sources: Fierce PharmaSTAT

About the Author
  • Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
JUL 05, 2021
Drug Discovery & Development
ADHD Drug Reduces Daydreaming, Fatigue and Boredom
JUL 05, 2021
ADHD Drug Reduces Daydreaming, Fatigue and Boredom
Researchers led by New York University have found that a stimulant drug may be able to treat persistent daydreaming, fat ...
JUL 12, 2021
Drug Discovery & Development
Testosterone Supplements Reduce Heart Attack and Stroke Risk
JUL 12, 2021
Testosterone Supplements Reduce Heart Attack and Stroke Risk
Taking testosterone supplements significantly reduces risk of heart attack and stroke among men with low levels of the h ...
AUG 13, 2021
Drug Discovery & Development
Breast Cancer Drug Reverses Deadly Blood Cancer in Mice
AUG 13, 2021
Breast Cancer Drug Reverses Deadly Blood Cancer in Mice
A drug currently used to treat advanced breast cancers may treat a rare type of leukemia known as myelofibrosis. The stu ...
SEP 10, 2021
Technology
"Shelf-Stable" COVID-19 Vaccine Candidate Made From Plant and Bacteria Viruses
SEP 10, 2021
"Shelf-Stable" COVID-19 Vaccine Candidate Made From Plant and Bacteria Viruses
Every day, researchers are making progress on therapeutics that could help end the COVID-19 pandemic. The FDA recently a ...
SEP 21, 2021
Drug Discovery & Development
Lifesaving TheraSpheres - glass microbeads can target and destroy colorectal tumors
SEP 21, 2021
Lifesaving TheraSpheres - glass microbeads can target and destroy colorectal tumors
The innovative medical device manufacturer Boston Scientific recently showed success in treating patients with ...
SEP 26, 2021
Coronavirus
LIBRA-Seq ID's a Potent Antibody to Fight COVID-19
SEP 26, 2021
LIBRA-Seq ID's a Potent Antibody to Fight COVID-19
Humans can produce millions or even billions of antibodies, so only so many can be captured and screened. But those anti ...
Loading Comments...